AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Free for Weaning ECMO vs Respiratory Driven Study

RecruitingNAAges 18 Years - anyAllAssistance Publique Hopitaux De Marseille
💬

In plain words

What the trial is, and whether it could suit you

In its most severe form, Acute Respiratory Distress Syndrome (ARDS) may require the use of veno-venous ECMO (vvECMO). While the criteria for vvECMO indication, ECMO settings, and ventilator management are relatively well-defined after the publication of the EOLIA trial and subsequent national or international guidelines, few studies have assessed the criteria and methods for weaning from vvECMO. Besides, advances in the understanding of the pathophysiology of mechanical ventilation (MV) weaning process have led to the development of specific monitoring tools for this phase. Schematically, respiratory drive can be evaluated via the ventilator by measuring the pressure generated during a 100-millisecond expiratory occlusion (P0.1) and respiratory efforts through the measurement of esophageal pressure variation (delta Poeso). Recent retrospective studies conducted on COVID-19 ARDS patient

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * Adult patients aged 18 years or older Patient whose trusted person has given consent for participation in the study * Patient on veno-venous ECMO with weaning criteria, including: * Resolution of the cause of ARDS * Absence of hemodynamic instability, defined as norepinephrine dose ≤ 0.5 μg/kg/min for at least 3 hours * Use of a ventilatory mode that allows spontaneous ventilation (VS-AI, BiPAP, or APRV) * Maximum inspiratory pressure ≤ 28 cm H2O, with a maximum driving pressure ≤ 15 cm H2O, enabling tidal volumes between 4 and 8 ml/kg of predicted body weight (PBW) * ECMO membrane sweep flow ≤ 2 L/min * Patient protected by social security Exclusion Criteria: * Contraindication to the placement of an esophageal pressure balloon (e.g., esophageal varices, nasal trauma, uncontrolled coagulopathy, severe thrombocytopenia), * Patient with treatment limitation at the time of inclusion, * Patient in the time frame of exclusion from another research protocol at the time of consent signing, * Vulnerable patients: minor, adult patient under guardianship or curatorship, patient deprived of liberty, pregnant or breastfeeding woman.
💊

What it tests

  • P0.1 and delta Poeso integration into the decanulation decision
📍

Where

4 sites
Hospices Civiles de Lyon
Lyon, France
Assistance - Publique Hôpitaux de Marseille
Marseille, France
CHU de Nice
Nice, France
Assistance Publique - Hôpitaux de Paris
Paris, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy